Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2001; 36(3): 134-142
DOI: 10.1055/s-2001-11814
ÜBERSICHT
© Georg Thieme Verlag Stuttgart · New York

Therapie des akuten Nierenversagens - Konzepte und Kontroversen

Teil I - Pharmakologische Behandlung und experimentelle TherapieansätzeA. GabrielE. MüllerJ. Tarnow
  • Institut für Klinische Anaesthesiologie (Direktor: Univ.-Professor Dr. med. J. Tarnow)
  • Heinrich-Heine-Universität Düsseldorf
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung.

Das akute Nierenversagen ist die gemeinsame Endstrecke vielfältiger Schädigungsereignisse. Die Prophylaxe und differenzierte Therapie dieses Krankheitsbildes ist in der Anästhesie und Intensivmedizin von großer Bedeutung. Eine pharmakologische Beeinflussung des akuten Nierenversagens ist nur in engen Grenzen möglich. Diuretika steigern zwar den Harnfluss, verbessern aber weder den Verlauf noch die Prognose des akuten Nierenversagens. Dopamin und natriuretische Peptide sind in der Prophylaxe und Behandlung nicht indiziert. Calcium-Antagonisten spielen lediglich bei der Nierentransplantation eine Rolle. Osmodiuretika verhindern die intratubuläre Präzipitation von Hämoglobin und Myoglobin; sie haben auch bei der Nierentransplantation prophylaktischen Wert. Experimentelle Ansätze zur Förderung der Regeneration der Tubuluszelle durch verschiedene Wachstumsfaktoren sind in vitro und im Tierversuch zwar vielversprechend, doch konnte ihr Nutzen bei der klinischen Applikation nicht belegt werden. Die Physiologie von Stickstoffmonoxid ist in der Niere noch unzureichend untersucht. Fortschritte zeichnen sich beim Verständnis der Lipidperoxidationsprozesse und ihrer pharmakologischen Beeinflussung ab. Entscheidend für die Klinik bleiben die rechtzeitige Erkennung des Risikopatienten und die konsequente Vermeidung nierenschädigender Situationen und Noxen.

Rational Pharmacotherapy and Experimental Strategies in the Treatment of Acute Renal Failure.

Acute renal failure is the common result of various damaging mechanisms. Prophylaxis and differentiated therapy of acute renal failure are of outmost importance in anaesthesiology and intensive care medicine. The efficiency of pharmacotherapy is narrowly limited. Diuretics increase the urine output, but they do neither ameliorate the clinical course of the patient nor the prognosis of established acute renal failure. Dopamine and natriuretic peptides have no use in prevention and treatment of acute renal failure. Calcium-channel-blockers are valuable in cadaveric kidney transplantation. Osmodiuretics prevent intratubular precipitation of hemoglobin and myoglobin crystals; they also have some value in cadaveric kidney transplantation. Experimental studies investigated the possibility to enhance the regeneration of the tubular epithelial cell. Whereas in vitro studies and studies in animal models using various growth factors yielded promising results, these could not be reproduced in patients with acute renal failure. The physiology of NO in the kidney is incompletely understood. Actual progress is made in the understanding of lipid peroxidation and potential pharmacological implications. The mainstay for the assurance of high-quality patient care remain a vigilant identification of the patient at risk and an arduous search to avoid nephrotoxic substances and situations implicating potential renal damage.

Schlüsselwörter:

Akutes Nierenversagen - Pharmakotherapie - Wachstumsfaktoren - Lipidperoxidation

Key words:

Acute renal failure - Pharmacotherapy - Growth factors - Lipid peroxidation

Literatur

  • 1 Feest T G, Round A, Hamad S. Incidence of severe acute renal failure in adults: results of a community based study.  BMJ. 1993;  306 481-483
    PubMedGoogle Scholar
  • 2 Liano F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study.  Madrid Acute Renal Failure Study Group Kidney Int. 1996;  50 811-818
    CrossrefPubMedGoogle Scholar
  • 3 Khan I H, Catto G R, Edward N, Macleod A M. Acute renal failure: factors influencing nephrology referral and outcome.  QJ Med. 1997;  90 781-785
    PubMedGoogle Scholar
  • 4 Morris J A, Mucha P, Ross S E, Moore B F, Hoyt D B, Gentilello L, Landercasper J, Feliciano D V, Shackford S R. Acute posttraumatic renal failure: a multicenter perspective.  J Trauma. 1991;  31 1584-1590
    PubMedGoogle Scholar
  • 5 Vivino G, Antonelli M, Moro M L, Cottini F, Conti G, Bufi M, Cannata F, Gasparetto A. Risk factors for acute renal failure in trauma patients.  Intensive Care Med. 1998;  24 808-814
    CrossrefPubMedGoogle Scholar
  • 6 McCullough P A, Wolyn R, Rocher L L, Levin R N, O'Neill W W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality.  Am J Med. 1997;  103 368-375
    CrossrefPubMedGoogle Scholar
  • 7 Suen W S, Mok C K, Chiu S W, Cheung K L, Lee W T, Cheung D, Das S R, He G W. Risk factors for development of acute renal failure (ARF) requiring dialysis in patients undergoing cardiac surgery.  Angiology. 1998;  49 789-800
    PubMedGoogle Scholar
  • 8 Schwilk B, Wiedeck H, Stein B, Reinelt H, Treiber H, Bothner U. Epidemiology of acute renal failure and outcome of haemodiafiltration in intensive care.  Intensive Care Med. 1997;  23 1204-1211
    CrossrefPubMedGoogle Scholar
  • 9 Wilkins R G, Faragher E B. Acute renal failure in an intensive care unit: incidence, prediction and outcome.  Anaesthesia. 1983;  38 628-634
    PubMedGoogle Scholar
  • 10 Turney J H, Marshall D H, Brownjohn A M, Ellis C M, Parsons F M. The evolution of acute renal failure, 1956 - 1988.  Q J Med. 1990;  74 83-104
    PubMedGoogle Scholar
  • 11 Barton I K, Hilton P J, Taub N A, Warburton F G, Swan A V, Dwight J, Mason J C. Acute renal failure treated by haemofiltration: factors affecting outcome [published erratum appears in Q J Med 1993 Apr;86(4):283].  Q J Med. 1993;  86 81-90
    PubMedGoogle Scholar
  • 12 Chew S L, Lins R L, Daelemans R, De Broe M E. Outcome in acute renal failure.  Nephrol Dial Transplant. 1993;  8 101-107
    PubMedGoogle Scholar
  • 13 Klouche K, Cristol J P, Kaaki M, Turc-Baron C, Canaud B, Beraud J J. Prognosis of acute renal failure in the elderly.  Nephrol Dial Transplant. 1995;  10 2240-2243
    PubMedGoogle Scholar
  • 14 Brivet F G, Kleinknecht D J, Loirat P, Landais P J. Acute renal failure in intensive care units-causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure.  Crit Care Med. 1996;  24 192-198
    CrossrefPubMedGoogle Scholar
  • 15 Liano F. Severity of acute renal failure: the need of measurement.  Nephrol Dial Transplant. 1994;  9 229-238
    PubMedGoogle Scholar
  • 16 Kierdorf H, Sieberth H G. Continuous treatment modalities in acute renal failure.  Nephrol Dial Transplant. 1995;  10 2001-2008
    PubMedGoogle Scholar
  • 17 Swartz R D, Messana J M, Orzol S, Port F K. Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure.  Am J Kidney Dis. 1999;  34 424-432
    PubMedGoogle Scholar
  • 18 Parker R A, Himmelfarb J, Tolkoff-Rubin N, Chandran P, Wingard R L, Hakim R M. Prognosis of patients with acute renal failure requiring dialysis: results of a multicenter study.  Am J Kidney Dis. 1998;  32 432-443
    CrossrefPubMedGoogle Scholar
  • 19 Van Den Noortgate N, Vogelaers D, Afschrift M, Colardyn F. Intensive care for very elderly patients: outcome and risk factors for in-hospital mortality.  Age Ageing. 1999;  28 253-256
    CrossrefPubMedGoogle Scholar
  • 20 Conger J D. Interventions in clinical acute renal failure: what are the data?.  Am J Kidney Dis. 1995;  26 565-576
    PubMedGoogle Scholar
  • 21 Vijayan A, Miller S B. Acute renal failure: prevention and nondialytic therapy.  Semin Nephrol. 1998;  18 523-532
    PubMedGoogle Scholar
  • 22 Solez K, Morel-Maroger L, Sraer J D. The morphology of „acute tubular necrosis” in man: analysis of 57 renal biopsies and a comparison with the glycerol model.  Medicine (Baltimore). 1979;  58 362-376
    PubMedGoogle Scholar
  • 23 Conger J. Does hemodialysis delay recovery from acute renal failure?.  Semin Dial. 1990;  3 146-148
    PubMedGoogle Scholar
  • 24 Brater D C. Diuretic therapy.  N Engl J Med. 1998;  339 387-395
    CrossrefPubMedGoogle Scholar
  • 25 Allison M E, Shilliday I. Loop diuretic therapy in acute and chronic renal failure.  J Cardiovasc Pharmacol. 1993;  22 S59-70
    PubMedGoogle Scholar
  • 26 Shilliday I, Allison M E. Diuretics in acute renal failure.  Ren Fail. 1994;  16 3-17
    PubMedGoogle Scholar
  • 27 Hans B, Hans S S, Mittal V K, Khan T A, Patel N, Dahn M S. Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency.  Radiology. 1990;  176 651-654
    PubMedGoogle Scholar
  • 28 Brown C B, Ogg C S, Cameron J S. High dose frusemide in acute renal failure: a controlled trial.  Clin Nephrol. 1981;  15 90-96
    PubMedGoogle Scholar
  • 29 Cantarovich F, Galli C, Benedetti L, Chena C, Castro L, Correa C, Perez Loredo J, Fernandez J C, Locatelli A, Tizado J. High dose frusemide in established acute renal failure.  Br Med J. 1973;  4 449-450
    PubMedGoogle Scholar
  • 30 Shilliday I R, Quinn K J, Allison M E. Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study.  Nephrol Dial Transplant. 1997;  12 2592-2596
    CrossrefPubMedGoogle Scholar
  • 31 Halpern N A, Pastores S M, Price J B, Alicea M. Hearing loss in critical care: an unappreciated phenomenon.  Crit Care Med. 1999;  27 211-219
    PubMedGoogle Scholar
  • 32 Thadhani R, Pascual M, Bonventre J V. Acute renal failure [see comments].  N Engl J Med. 1996;  334 1448-1460
    CrossrefPubMedGoogle Scholar
  • 33 Better O S, Stein J H. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis [see comments].  N Engl J Med. 1990;  322 825-829
    PubMedGoogle Scholar
  • 34 van Valenberg P L, Hoitsma A J, Tiggeler R G, Berden J H, van Lier H J, Koene R A. Mannitol as an indispensable constituent of an intraoperative hydration protocol for the prevention of acute renal failure after renal cadaveric transplantation.  Transplantation. 1987;  44 784-788
    PubMedGoogle Scholar
  • 35 Gubern J M, Sancho J J, Simo J, Sitges-Serra A. A randomized trial on the effect of mannitol on postoperative renal function in patients with obstructive jaundice.  Surgery. 1988;  103 39-44
    PubMedGoogle Scholar
  • 36 Gubern J M, Martinez-Rodenas F, Sitges-Serra A. Use of mannitol as a measure to prevent postoperative renal failure in patients with obstructive jaundice.  Am J Surg. 1990;  159 444-445
    PubMedGoogle Scholar
  • 37 Old C W, Lehrner L M. Prevention of radiocontrast induced acute renal failure with mannitol.  Lancet. 1980;  1 885
    PubMedGoogle Scholar
  • 38 Anto H R, Chou S Y, Porush J G, Shapiro W B. Infusion intravenous pyelography and renal function. Effect of hypertonic mannitol in patients with chronic renal insufficiency.  Arch Intern Med. 1981;  141 1652-1656
    CrossrefPubMedGoogle Scholar
  • 39 Weisberg L S, Kurnik P B, Kurnik B R. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus.  Kidney Int. 1994;  45 259-265
    PubMedGoogle Scholar
  • 40 McDonald R, Goldberg L, McNay J, Tuttle E. Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow.  J Clin Invest. 1964;  43 1116-1124
    CrossrefPubMedGoogle Scholar
  • 41 Singer I, Epstein M. Potential of dopamine A- 1 agonists in the management of acute renal failure.  Am J Kidney Dis. 1998;  31 743-755
    PubMedGoogle Scholar
  • 42 Myles P S, Buckland M R, Schenk N J, Cannon G B, Langley M, Davis B B, Weeks A M. Effect of “renal-dose” dopamine on renal function following cardiac surgery.  Anaesth Intensive Care. 1993;  21 56-61
    PubMedGoogle Scholar
  • 43 Weisberg L S, Kurnik P B, Kurnik B R. Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans.  Ren Fail. 1993;  15 61-68
    PubMedGoogle Scholar
  • 44 Hans S S, Hans B A, Dhillon R, Dmuchowski C, Glover J. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency.  Am Surg. 1998;  64 432-436
    PubMedGoogle Scholar
  • 45 Abizaid A S, Clark C E, Mintz G S, Dosa S, Popma J J, Pichard A D, Satler L F, Harvey M, Kent K M, Leon M B. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency.  Am J Cardiol. 1999;  83 260-263, A265
    CrossrefPubMedGoogle Scholar
  • 46 Lumlertgul D, Keoplung M, Sitprija V, Moollaor P, Suwangool P. Furosemide and dopamine in malarial acute renal failure.  Nephron. 1989;  52 40-44
    PubMedGoogle Scholar
  • 47 Epstein M. Calcium antagonists and the kidney.  J Cardiovasc Pharmacol. 1994;  24 S18-24
    PubMedGoogle Scholar
  • 48 Wagner K, Albrecht S, Neumayer H H. [Protective effect of the calcium antagonist diltiazem on acute kidney failure following kidney transplantation. The results of a prospective randomized study].  Dtsch Med Wochenschr. 1986;  111 1363-1367
    PubMedGoogle Scholar
  • 49 Neumayer H H, Wagner K. Prevention of delayed graft function in cadaver kidney transplants by diltiazem: outcome of two prospective, randomized clinical trials.  J Cardiovasc Pharmacol. 1987;  10 S170-177
    PubMedGoogle Scholar
  • 50 Neumayer H H, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation.  Kidney Int Suppl. 1992;  36 S87-93
    PubMedGoogle Scholar
  • 51 Wagner K, Neumayer H H. Influence of the calcium antagonist diltiazem on delayed graft function in cadaveric kidney transplantation: results of a 6-month follow-up.  Transplant Proc. 1987;  19 1353-1357
    PubMedGoogle Scholar
  • 52 Lewis R, Katz S, Van Buren C, Kerman R, Kahan B. Mechanisms and amelioration of acute renal allograft failure in the cyclosporine era.  Ren Fail. 1992;  14 267-284
    PubMedGoogle Scholar
  • 53 Young E W, Diab A, Kirsh M M. Intravenous diltiazem and acute renal failure after cardiac operations.  Ann Thorac Surg. 1998;  65 1316-1319
    CrossrefPubMedGoogle Scholar
  • 54 Forssmann W G, Richter R, Meyer M. The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system.  Histochem Cell Biol. 1998;  110 335-357
    CrossrefPubMedGoogle Scholar
  • 55 Forssmann W G. Urodilatin (ularitide, INN): a renal natriuretic peptide. Molecular biology and clinical importance.  Nephron. 1995;  69 211-222
    PubMedGoogle Scholar
  • 56 Zeidel M L. Hormonal regulation of inner medullary collecting duct sodium transport [editorial].  Am J Physiol. 1993;  265 F159-173
    PubMedGoogle Scholar
  • 57 Jensen K T, Carstens J, Pedersen E B. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans.  Am J Physiol. 1998;  274 F63-72
    PubMedGoogle Scholar
  • 58 Rahman S N, Kim G E, Mathew A S, Goldberg C A, Allgren R, Schrier R W, Conger J D. Effects of atrial natriuretic peptide in clinical acute renal failure.  Kidney Int. 1994;  45 1731-1738
    PubMedGoogle Scholar
  • 59 Allgren R L, Marbury T C, Rahman S N, Weisberg L S, Fenves A Z, Lafayette R A, Sweet R M, Genter F C, Kurnik B R, Conger J D, Sayegh M H. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group.  N Engl J Med. 1997;  336 828-834
    CrossrefPubMedGoogle Scholar
  • 60 Klahr S, Miller S B. Acute oliguria.  N Engl J Med. 1998;  338 671-675
    CrossrefPubMedGoogle Scholar
  • 61 Hummel M, Kuhn M, Bub A, Bittner H, Kleefeld D, Marxen P, Schneider B, Hetzer R, Forssmann W G. Urodilatin: a new peptide with beneficial effects in the postoperative therapy of cardiac transplant recipients.  Clin Investig. 1992;  70 674-682
    PubMedGoogle Scholar
  • 62 Kuse E R, Meyer M, Constantin R, Oldhafer K, Schlitt H J, Schulz-Knappe P, Uberbacher H J, Pichlmayr R, Forssmann W G. [Urodilatin (INN: ularitide). A new peptide in the treatment of acute kidney failure following liver transplantation].  Anaesthesist. 1996;  45 351-358
    CrossrefPubMedGoogle Scholar
  • 63 Meyer M, Richter R, Forssmann W G. Urodilatin, a natriuretic peptide with clinical implications.  Eur J Med Res. 1998;  3 103-110
    PubMedGoogle Scholar
  • 64 Meyer M, Pfarr E, Schirmer G, Uberbacher H J, Schope K, Bohm E, Fluge T, Mentz P, Scigalla P, Forssmann W G. Therapeutic use of the natriuretic peptide ularitide in acute renal failure.  Ren Fail. 1999;  21 85-100
    PubMedGoogle Scholar
  • 65 Herbert M K, Ginzel S, Muhlschlegel S, Weis K H. Concomitant treatment with urodilatin (ularitide) does not improve renal function in patients with acute renal failure after major abdominal surgery - a randomized controlled trial [see comments].  Wien Klin Wochenschr. 1999;  111 141-147
    PubMedGoogle Scholar
  • 66 Osswald H, Gleiter C, Muhlbauer B. Therapeutic use of theophylline to antagonize renal effects of adenosine.  Clin Nephrol. 1995;  43 (Suppl 1) S33-37
    PubMedGoogle Scholar
  • 67 Heidemann H T, Bolten M, Inselmann G. Effect of chronic theophylline administration on amphotericin B nephrotoxicity in rats.  Nephron. 1991;  59 294-298
    PubMedGoogle Scholar
  • 68 Heidemann H T, Muller S, Mertins L, Stepan G, Hoffmann K, Ohnhaus E E. Effect of aminophylline on cisplatin nephrotoxicity in the rat.  Br J Pharmacol. 1989;  97 313-318
    PubMedGoogle Scholar
  • 69 Bidani A K, Churchill P C. Aminophylline ameliorates glycerol-induced acute renal failure in rats.  Can J Physiol Pharmacol. 1983;  61 567-571
    PubMedGoogle Scholar
  • 70 Bidani A K, Churchill P C, Packer W. Theophylline-induced protection in myoglobinuric acute renal failure: further characterization.  Can J Physiol Pharmacol. 1987;  65 42-45
    PubMedGoogle Scholar
  • 71 Erley C M, Duda S H. [Contrast media-associated nephropathy - pathogenesis and prevention].  Aktuelle Radiol. 1997;  7 189-192
    PubMedGoogle Scholar
  • 72 Erley C M, Duda S H, Schlepckow S, Koehler J, Huppert P E, Strohmaier W L, Bohle A, Risler T, Osswald H. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application.  Kidney Int. 1994;  45 1425-1431
    PubMedGoogle Scholar
  • 73 Erley C M, Heyne N, Burgert K, Langanke J, Risler T, Osswald H. Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency.  J Am Soc Nephrol. 1997;  8 1125-1132
    PubMedGoogle Scholar
  • 74 Katholi R E, Taylor G J, McCann W P, Woods W T, Womack K A, McCoy C D, Katholi C R, Moses H W, Mishkel G J, Lucore C L. et al . Nephrotoxicity from contrast media: attenuation with theophylline.  Radiology. 1995;  195 17-22
    PubMedGoogle Scholar
  • 75 Erley C M, Duda S H, Rehfuss D, Scholtes B, Bock J, Muller C, Osswald H, Risler T. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline.  Nephrol Dial Transplant. 1999;  14 1146-1149
    PubMedGoogle Scholar
  • 76 Erley C M, Heyne N, Rossmeier S, Vogel T, Risler T, Osswald H. Adenosine and extracellular volume in radiocontrast media-induced nephropathy.  Kidney Int Suppl. 1998;  67 S192-194
    PubMedGoogle Scholar
  • 77 Erley C M. Does hydration prevent radiocontrast-induced acute renal failure?.  Nephrol Dial Transplant. 1999;  14 1064-1066
    CrossrefPubMedGoogle Scholar
  • 78 Davies J A, Davey M G. Collecting duct morphogenesis.  Pediatr Nephrol. 1999;  13 535-541
    CrossrefPubMedGoogle Scholar
  • 79 Gobe G, Zhang X J, Cuttle L, Pat B, Willgoss D, Hancock J, Barnard R, Endre R B. Bcl-2 genes and growth factors in the pathology of ischaemic acute renal failure.  Immunol Cell Biol. 1999;  77 279-286
    CrossrefPubMedGoogle Scholar
  • 80 Schena F P. Role of growth factors in acute renal failure.  Kidney Int Suppl. 1998;  66 S11-15
    PubMedGoogle Scholar
  • 81 Schena F P, Strippoli G F, Wankelmuth P. Renal growth factors: past, present and future.  Am J Nephrol. 1999;  19 308-312
    CrossrefPubMedGoogle Scholar
  • 82 Liu Y. Hepatocyte growth factor promotes renal epithelial cell survival by dual mechanisms.  Am J Physiol. 1999;  277 F624-633
    PubMedGoogle Scholar
  • 83 Ho R T, Liew C T, Lai K N. The expression of hepatocyte growth factor (HGF) and interleukin 6 (IL-6) in damaged human liver and kidney tissues.  Hepatogastroenterology. 1999;  46 1904-1909
    PubMedGoogle Scholar
  • 84 Barasch J. FGF-2: specific activity in kidney?.  Kidney Int. 1999;  56 1156-1157
    CrossrefPubMedGoogle Scholar
  • 85 Cuevas P, Martinez-Coso V, Fu X, Orte L, Reimers D, Gimenez-Gallego G, Forssmann W G, Saenz De Tejada I. Fibroblast growth factor protects the kidney against ischemia-reperfusion injury.  Eur J Med Res. 1999;  4 403-410
    PubMedGoogle Scholar
  • 86 Nakagawa T, Sasahara M, Haneda M, Kataoka H, Nakagawa H, Yagi M, Kikkawa R, Hazama F. Role of PDGF B-chain and PDGF receptors in rat tubular regeneration after acute injury.  Am J Pathol. 1999;  155 1689-1699
    PubMedGoogle Scholar
  • 87 Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, Henninger D D, Janjic N, Floege J. VEGF(165) mediates glomerular endothelial repair.  J Clin Invest. 1999;  104 913-923
    CrossrefPubMedGoogle Scholar
  • 88 Kostecka Y, Blahovec J. Insulin-like growth factor binding proteins and their functions (minireview).  Endocr Regul. 1999;  33 90-94
    PubMedGoogle Scholar
  • 89 Baserga R, Sell C, Porcu P, Rubini M. The role of the IGF-I receptor in the growth and transformation of mammalian cells.  Cell Prolif. 1994;  27 63-71
    CrossrefPubMedGoogle Scholar
  • 90 Camacho-Hubner C, Woods K A, Miraki-Moud F, Clark A, Savage M O. Insulin-like growth factor-I deficiency caused by a partial deletion of the IGF-I gene: effects of rhIGF-I therapy.  Growth Horm IGF Res. 1999;  9 (Suppl B:) 47 - 51-discussion 51 - 42
    PubMedGoogle Scholar
  • 91 Rogers S A, Powell-Braxton L, Hammerman M R. Insulin-like growth factor I regulates renal development in rodents.  Dev Genet. 1999;  24 293-298
    CrossrefPubMedGoogle Scholar
  • 92 Hirschberg R, Adler S. Insulin-like growth factor system and the kidney: physiology, pathophysiology, and therapeutic implications.  Am J Kidney Dis. 1998;  31 901-919
    PubMedGoogle Scholar
  • 93 Hirschberg R, Ding H. Mechanisms of insulin-like growth factor-I-induced accelerated recovery in experimental ischemic acute renal failure.  Miner Electrolyte Metab. 1998;  24 211-219
    CrossrefPubMedGoogle Scholar
  • 94 Hammerman M R. The growth hormone-insulin-like growth factor axis in kidney re-revisited.  Nephrol Dial Transplant. 1999;  14 1853-1860
    PubMedGoogle Scholar
  • 95 Padanilam B J, Martin D R, Hammerman M R. Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rats.  Endocrinology. 1996;  137 2133-2140
    CrossrefPubMedGoogle Scholar
  • 96 Noiri E, Dickman K, Miller F, Romanov G, Romanov V I, Shaw R, Chambers A F, Rittling S R, Denhardt D T, Goligorsky M S. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene.  Kidney Int. 1999;  56 74-82
    CrossrefPubMedGoogle Scholar
  • 97 Vijayan A, Franklin S C, Behrend T, Hammerman M R, Miller S B. Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure.  Am J Physiol. 1999;  276 R929-934
    PubMedGoogle Scholar
  • 98 Franklin S C, Moulton M, Sicard G A, Hammerman M R, Miller S B. Insulin-like growth factor I preserves renal function postoperatively.  Am J Physiol. 1997;  272 F257-259
    PubMedGoogle Scholar
  • 99 Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T, Munger M, Metzler M, Zaloga G, Murray M, Lowry S, Conger J. et al . Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.  Kidney Int. 1999;  55 2423-2432
    CrossrefPubMedGoogle Scholar
  • 100 Humes H D. Acute renal failure - the promise of new therapies. .  N Engl J Med. 1997;  336 870-871
    CrossrefPubMedGoogle Scholar
  • 101 Kone B C. Nitric oxide in renal health and disease.  Am J Kidney Dis. 1997;  30 311-333
    CrossrefPubMedGoogle Scholar
  • 102 Thijs A, Thijs L G. Pathogenesis of renal failure in sepsis.  Kidney Int Suppl. 1998;  66 S34-37
    PubMedGoogle Scholar
  • 103 Nissenson A R. Acute renal failure: definition and pathogenesis.  Kidney Int Suppl. 1998;  66 S7-10
    PubMedGoogle Scholar
  • 104 Lieberthal W. Biology of ischemic and toxic renal tubular cell injury: role of nitric oxide and the inflammatory response.  Curr Opin Nephrol Hypertens. 1998;  7 289-295
    PubMedGoogle Scholar
  • 105 Goligorsky M S, Noiri E. Duality of nitric oxide in acute renal injury.  Semin Nephrol. 1999;  19 263-271
    PubMedGoogle Scholar
  • 106 Jerkic M, Varagic J, Jovovic D, Radujkovic-Kuburovic G, Nastic-Miric D, Adanja-Grujic G, Markovic-Lipkovski J, Dimitrijevic J, Miloradovic Z, Vojvodic S B. L-arginine reduces tubular cell injury in acute post-ischaemic renal failure.  Nephrol Dial Transplant. 1999;  14 1398-1407
    PubMedGoogle Scholar
  • 107 Matsumura Y, Nishiura M, Deguchi S, Hashimoto N, Ogawa T, Seo R. Protective effect of FK409, a spontaneous nitric oxide releaser, on ischemic acute renal failure in rats.  J Pharmacol Exp Ther. 1998;  287 1084-1091
    PubMedGoogle Scholar
  • 108 Poovala V S, Kanji V K, Tachikawa H, Salahudeen A K. Role of oxidant stress and antioxidant protection in acephate-induced renal tubular cytotoxicity.  Toxicol Sci. 1998;  46 403-409
    CrossrefPubMedGoogle Scholar
  • 109 Salahudeen A K, Wang C, Bigler S A, Dai Z, Tachikawa H. Synergistic renal protection by combining alkaline-diuresis with lipid peroxidation inhibitors in rhabdomyolysis: possible interaction between oxidant and non-oxidant mechanisms.  Nephrol Dial Transplant. 1996;  11 635-642
    PubMedGoogle Scholar
  • 110 Salahudeen A, Badr K, Morrow J, Roberts J. Hydrogen peroxide induces 21-aminosteroid-inhibitable F2-isoprostane production and cytolysis in renal tubular epithelial cells.  J Am Soc Nephrol. 1995;  6 1300-1303
    PubMedGoogle Scholar
  • 111 Salahudeen A, Nawaz M, Poovala V, Kanji V, Wang C, Morrow J, Roberts J 2nd . Cold storage induces time-dependent F2-isoprostane formation in renal tubular cells and rat kidneys.  Kidney Int. 1999;  55 1759-1762
    CrossrefPubMedGoogle Scholar

Dr. med. Andrea Gabriel

Institut für Klinische Anaesthesiologie
Heinrich-Heine-Universität

Moorenstr. 5

40225 Düsseldorf

      >